

Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes

Paul J. Norman,¹ Laurent Abi-Rached,¹ Ketevan Gendzekhadze,¹ John A. Hammond,¹ Achim K. Moesta,¹ Deepti Sharma,¹ Thorsten Graef,¹ Karina L. McQueen,¹ Lisbeth A. Guethlein,¹ Christine V.F. Carrington,² Dasdayanee Chandanayingyong,³ Yih-Hsin Chang,⁴ Catalina Crespi,⁵ Güher Saruhan-Direskeneli,⁶ Kamran Hameed,⁷ Giorgi Kamkamidze,⁸ Kwadwo A. Koram,⁹ Zulay Layrisse,¹⁰ Nuria Matamoros,⁵ Joan Milà,⁵ Myoung Hee Park,¹¹ Ramasamy M. Pitchappan,¹² D. Dan Ramdath,² Ming-Yuh Shiau,¹³ Henry A.F. Stephens,¹⁴ Siske Struik,¹⁵ Dolly Tyan,¹⁶ David H. Verity,¹⁷ Robert W. Vaughan,¹⁸ Ronald W. Davis,¹⁹ Patricia A. Fraser,²⁰ Eleanor M. Riley,¹⁵ Mostafa Ronaghi,¹⁹ and Peter Parham^{1,21}

^{1–20}[A complete list of author affiliations appears at the end of the paper before the Acknowledgments section.]

Natural killer (NK) cells contribute to the essential functions of innate immunity and reproduction. Various genes encode NK cell receptors that recognize the major histocompatibility complex (MHC) Class I molecules expressed by other cells. For primate NK cells, the killer-cell immunoglobulin-like receptors (KIR) are a variable and rapidly evolving family of MHC Class I receptors. Studied here is *KIR3DL1/S1*, which encodes receptors for highly polymorphic human HLA-A and -B and comprises three ancient allelic lineages that have been preserved by balancing selection throughout human evolution. While the 3DSI lineage of activating receptors has been conserved, the two 3DLI lineages of inhibitory receptors were diversified through inter-lineage recombination with each other and with 3DSI. Prominent targets for recombination were DO-domain polymorphisms, which modulate enhancer function, and dimorphism at position 283 in the D2 domain, which influences inhibitory function. In African populations, unequal crossing over between the *3DL1* and *3DL2* genes produced a deleted *KIR* haplotype in which the telomeric “half” was reduced to a single fusion gene with functional properties distinct from its *3DL1* and *3DL2* parents. Conversely, in Eurasian populations, duplication of the *KIR3DL1/S1* locus by unequal crossing over has enabled individuals to carry and express alleles of all three *KIR3DL1/S1* lineages. These results demonstrate how meiotic recombination combines with an ancient, preserved diversity to create new *KIR* phenotypes upon which natural selection acts. A consequence of such recombination is to blur the distinction between alleles and loci in the rapidly evolving human *KIR* gene family.

[Supplemental material is available online at www.genome.org. The sequence data from this study have been submitted to GenBank (<http://www.ncbi.nlm.nih.gov/Genbank/>) under accession nos. EF582383, EU267269–71, FJ158650–60, and FJ459734.]

Among the most polymorphic and structurally diverse human loci are genes related to immune function (Redon et al. 2006; Frazer et al. 2007; Korbel et al. 2007). A principle example is the *KIR* locus, which displays both polymorphic and structural diversity throughout all human populations (Parham 2005; Bashirova et al. 2006). The protein products, the killer cell immunoglobulin-like receptors (KIR), recognize determinants of conserved and polymorphic major histocompatibility complex (MHC) Class I molecules (Boyington et al. 2001). Interaction of KIR on immune-system cells with MHC Class I on other cell types allows the health of tissues to be monitored and responded to when compromised by infection or malignant transformation. In the human MHC, the HLA complex, each of the highly polymorphic Class I genes—*HLA-A*, *HLA-B*, and *HLA-C*—has some alleles that encode KIR ligands. KIR are principally found on the surface of natural killer

(NK) cells, lymphocytes that function in the early, or innate, immune response to virus infection (Lanier 2008), but they also contribute to an early stage of reproduction, when they remodel the maternal blood vessels that will supply the placenta and nourish the fetus (Moffett and Loke 2006). KIR are also expressed on some T-lymphocytes, cells that are central to the adaptive immune response to infection (Snyder et al. 2004; Moretta et al. 2006).

In humans and other primates, the KIR are encoded by a diverse and rapidly evolving gene family that exhibits considerable species specificity due to continual gene turnover (Parham 2005; Bashirova et al. 2006). In contrast, in mice, the widely used animal model in immunology, the *KIR* genes are few in number (two) and do not encode NK cell receptors for MHC Class I, those functions having been assumed by the independently evolved KLRA1 (also known as Ly49) receptors (Kelley et al. 2005). This lability and plasticity in genes encoding NK cell receptors likely reflects the strengths of the different and sometimes conflicting selections imposed by the needs of immune defense and placental

²¹Corresponding author.

E-mail peropa@stanford.edu; fax (650) 723-7456.

Article is online at <http://www.genome.org/cgi/doi/10.1101/gr.085738.108>.

reproduction, but also by the functional and genetic complexity of matching polymorphic ligands and receptors encoded by unlinked genes (Parham 2005; Moffett and Loke 2006; Lanier 2008).

The *KIR* locus is part of the leukocyte receptor complex (LRC) on human chromosome 19, which comprises several families of cell-surface receptors expressed by cells of the immune system (Wilson et al. 2000). The *KIR* genes are flanked on the centromeric side by the leukocyte immunoglobulin-like receptor (*LILR*) gene family and on the telomeric side by *FCAR*, the gene encoding the receptor for immunoglobulin A that is expressed on phagocytic cells. Human *KIR* haplotypes vary in gene content, having between seven and 15 genes (Uhrberg et al. 1997). Each *KIR* haplotype is divided into two parts by three conserved framework regions. The centromeric part contains *KIR2D* genes encoding HLA-C receptors, and the telomeric part contains *KIR3D* genes encoding HLA-A and -B receptors (Bashirova et al. 2006). The latter two genes, comprising *KIR3DL1/S1* and *KIR3DL2*, are the subject of this study. *KIR3DL1/S1* recognizes sequence motifs at residues 77–83 of HLA-A and HLA-B allotypes that form the Bw4 antigen, or epitope, defined by HLA serology (Cella et al. 1994; Gumperz et al. 1995; Thananchai et al. 2007), and *KIR3DL2* recognizes HLA-A3 and -A11 (Dohring et al. 1996; Pende et al. 1996).

Like HLA-A and -B, *KIR3DL1/S1* is a highly polymorphic protein with more than 60 allotypes defined (Robinson et al. 2006). The natural variation affects receptor function by altering the frequency of cellular expression, abundance at the cell surface (Pando et al. 2003; Thomas et al. 2008), avidity and specificity for ligand (O'Connor et al. 2007; Thananchai et al. 2007), and the nature—either inhibitory or activating—of the intracellular signals generated upon ligand engagement (Carr et al. 2007). Furthermore, a person's combination of HLA-A, HLA-B, and *KIR3DL1/S1* allotypes influences the development and function of the NK cell repertoire (Foley et al. 2008; Yawata et al. 2008), and in the population, such combinations are associated with disease susceptibility and progression, notably for HIV infection (Martin et al. 2007). The foundation for *3DL1/S1* variety is three ancient lineages of alleles—*3DS1* lineage encoding activating receptors and *3DL1-005* and *015* lineages encoding inhibitory receptors—maintained by balancing selection for >3 million years and present in all modern human populations (Norman et al. 2007). Of the three lineages, *3DS1* is essentially homogeneous, whereas both *3DL1* lineages have been extensively diversified by point mutation and recombination. Because recombination with other *KIR* genes and between *KIR3DL1/S1* lineages has the potential to erode the lineage distinctions, we examined the impact that meiotic recombination has had on the *KIR3DL1/S1* locus and on human NK cell functional diversity.

Results

Generation of *KIR3DL1/S1* diversity by intergenic recombination

In humans, the hominoid *KIR* lineage II is represented by two genes: *3DL1/S1* encoding NK cell receptors for the Bw4 epitopes of HLA-A and HLA-B; and *3DL2* encoding NK-cell receptors specific for HLA-A*03 and HLA-A*11 (Rajalingam et al. 2004). Not fitting with this picture is the *3DL1/2v* cDNA, which encodes extracellular domains like *3DL1* and intracellular domains like *3DL2* (Shilling et al. 2002). To distinguish if the *3DL1/2v* cDNA arises from transcription of a single gene or the splicing together of transcripts from both *3DL1* and *3DL2*, we analyzed genomic DNA

from three healthy donors having different *3DL1/2v* variants and one *3DL1/2v* donor who lacked *3DL1/S1* because of deletion of this locus from the other *KIR* haplotype (Norman et al. 2004). The results unequivocally demonstrated that *3DL1/2v* represents a unique hybrid gene for which exons 1–5 and associated introns are like *3DL1*, and exons 6–9 and associated introns are like *3DL2* (Fig. 1A, upper haplotype). In all four donors, the *3DL1/2v* gene was shown to be flanked by *2DL4* on the upstream (centromeric) side and by *FCAR* on the downstream (telomeric) side. This gene organization is unusual, differing from the more common situation (Wilson et al. 2000) where *3DL1* is downstream from *2DL4*, *3DL2* is upstream of *FCAR*, and *2DS4* lies between *3DL1* and *3DL2* (Fig. 1A, lower haplotype). These results raised the possibility that *3DL1/2v* arose through a non-homologous recombination between *3DL1* and *3DL2* that deleted the 3' part of *3DL1*, the entire *2DS4* gene, and the 5' part of *3DL2*. If true, then individuals carrying *3DL1/2v* should never be heterozygous for exons 1–5 of *3DL2* or exons 6–9 of *3DL1/S1*. Population analysis was performed to test this hypothesis.

KIR3DL1/2v is restricted to sub-Saharan Africans and related populations such as African-Americans and Afro-Caribbeans, in which it is present at frequencies of up to 6.5% (Norman et al. 2007). Panels of 65 *3DL1/2v*⁺ and 65 *3DL1/2v*⁻ Africans were genotyped for heterozygosity in the sequences encoding the extracellular and intracellular domains of *3DL1* and *3DL2*, and also for *2DL4* as a control. Whereas the *3DL1/2v*⁻ Africans exhibited significant heterozygosity in both the 3' and 5' parts of the *3DL1* and *3DL2* genes, the *3DL1/2v*⁺ Africans lacked heterozygosity in the 3'-exons of *3DL1/S1* and the 5'-exons of *3DL2* (Fig. 1B). These results, showing that *3DL1/2v* is not on the same haplotypes as *3DL1* or *3DL2*, are consistent with *3DL1/2v* having been formed by a recombination-mediated deletion that fused exons 1–5 of *3DL1* with exons 6–9 of *3DL2*. As a consequence, *3DL1/2v* has an allelic relationship with both *3DL1* and *3DL2* (Supplemental Fig. S1). Because *3DL1/2v* is overall more structurally similar to *3DL1* than *3DL2*, the three *3DL1/2v* variants were assigned names in the *3DL1/S1* series: *3DL1*059*, *3DL1*060*, and *3DL1*061* (Robinson et al. 2006). The encoded allotypes, which differ by one or two amino acid substitutions, have extracellular domains that are part of the *3DL1-005* lineage, as opposed to the *3DL1-015* lineage (Fig. 1C). That *3DL1*059* is geographically most widespread, being present in all six African populations studied, compared to only one and two populations for *3DL1*060* and *3DL1*061*, respectively (Fig. 1D), suggests that *3DL1*059* was the progenitor *3DL1/2v* from which *3DL1*060* and *3DL1*061* were independently derived by single point substitutions. Further supporting this evolutionary model, the *3DL1*059* sequence corresponds to a fusion of sequences from common *3DL1* (e.g., **00501*) and *3DL2* (e.g., **001*) alleles, whereas *3DL1*060* and *3DL1*061* are each distinguished by a unique and different substitution. From the genomic sequences, the recombination that fused parts of the *3DL1* and *3DL2* genes to form *3DL1/2v* can be located to a 30-bp sequence within intron 5 that is located 356 bp upstream of exon 6, and 2780 bp downstream from exon 5 encoding the D2 domain (Fig. 1E; Supplemental Fig. S2).

The genomic location of *3DL1/2v* between *2DL4* and *FCAR* is the same as that observed for *Pt-KIR3DL1/2*, the single chimpanzee lineage II *KIR* gene (Rajalingam et al. 2004; Sambrook et al. 2005), which has structural and functional properties in common with both human *3DL1* and *3DL2* (Khakoo et al. 2000). Although these similarities raised the possibility that *3DL1/2v* and *Pt-KIR3DL1/2* share a common origin that predated the human–chimpanzee




Figure 1. The *3DL1/2v* fusion gene is allelic to *3DL1/S1* and *3DL2*. (A, top) Schematic of the four *3DL1/2v* haplotypes that were sequenced here (Supplemental Fig. S2). (Bottom) A *KIR A* haplotype; (dashed lines) the genomic segment absent from *3DL1/2v* haplotypes; (yellow) *3DL1*; (blue) *3DL2*. Exons 1–5 encode the leader peptide and Ig domains (Ig), exon 6 the stalk, and exons 7–9 the transmembrane and cytoplasmic domains (Tm/Cyt). (B, left) Representative genotypes from the group of 65 subjects who carry *3DL1/2v* (*3DL1/2v*⁺) and the group of 65 who do not (*3DL1/2v*⁻). (Right) Comparisons of heterozygosity observed in the *3DL1/2v*⁺ and *3DL1/2v*⁻ groups from segments of *3DL1* and *3DL2*. All of the *3DL1/2v*⁺ subjects are hemizygous for exons 6–9 of *3DL1/S1* and exons 1–5 of *3DL2*, which corresponds to the portion absent from the *KIR A* haplotype. This shows the *3DL1/2v*⁺ subjects have *3DL1* and *3DL2* on one haplotype and *3DL1/2v* on the other. (C) Shown are the nucleotide differences in exons 1–5 that distinguish *3DL1/2v* (*3DL1*059*, *3DL1*060*, and *3DL1*061*) from (white) *3DL1* and in exons 7–9 that distinguish *3DL1/2v* from (gray) *3DL2*. The many nucleotide differences ($N = 102$) that distinguish *3DL1* and *3DL2* are not shown. Shown are *3DL1*00501* and *3DL1*01502*, which represent the 005 and 015 lineages of inhibitory receptors; exons 1–5 of *3DL1/2v* are related to *3DL1*00501*. In exons 7–9, *3DL1*059* is identical to *3DL2*001*; *3DL1*060* and *3DL1*061* being distinguished by the SNPs boxed. Codons are numbered according to the mature protein, and amino acid changes are indicated by single letter code. (D) Shown are the frequencies of three *3DL1/2v* alleles (*3DL1*059–61*) in the five sub-Saharan African populations where they were detected. The number of haplotypes examined from each population is shown in parentheses; error bars show the 95% confidence interval of the allele frequency measurements. (E) Shown is a pairwise identity plot from alignment of genomic sequences. (Yellow line) Signifies identity of *3DL1/2v* with *3DL1*; (blue line) the identity of *3DL1/2v* with *3DL2*; (vertical bars) the SNP markers used in this analysis. (Shown below by the vertical arrow) The crossover occurred in intron 5 during the interval from 386 to 356 bp upstream from exon 6. A continuous sequence trace that spans the crossover is shown in Supplemental Figure S2.

separation, several lines of evidence point to *3DL1/2v* having evolved independently by recombination during human evolution, subsequent to the split from chimpanzees. First, the inclusion of exons 1–5 of *3DL1/2v* in the 005 lineage of *3DL1/S1* alleles (Fig. 1C), and not in either the 015 or *3DS1* lineages, indicates that *3DL1/2v* was formed after lineage divergence, which

regions of the molecule most affected by recombination are the D0 domain (five events) and position 283 (three events) near the C-terminal end of the D2 domain (Fig. 2A). Both these regions bear a strong signature of positive selection in human populations (Norman et al. 2007) and have distinct functions that affect the strength and specificity of the *KIR3DL1/S1* interaction with MHC

occurred subsequent to the human–chimpanzee separation (Norman et al. 2007). Thus in phylogenetic analysis, human *3DL1/2v* was never an out-group to *3DL1* when compared with *Pe-KIR3DL1/2* and other hominoid *KIR* lineage II genes (Supplemental Fig. S3A). Second, the *3DL1/2v* Ig-domain is estimated to have arisen ~0.74 million years ago (Mya) (95% CI: 0.27–1.55 Mya) (Supplemental Fig. S3B), after the three allelic lineages of *3DL1/S1* split. As the Ig-domain divergence preceded the genomic deletion event, *3DL1/2v* arose at a time potentially close to the emergence of modern humans (~200,000 yr ago) (Relethford 2008). Lastly, our finding that all three variants of *3DL1/2v* (*3DL1*059*, *3DL1*060*, *3DL1*061*) were flanked by identical sequences and *2DL4* (**00801*) and *FCAR* (**001*) alleles, despite genome-wide lack of LD in sub-Saharan Africans (Campbell and Tishkoff 2008), points to a recent origin for *3DL1/2v*.

In conclusion, the results are all consistent with *3DL1/2v* having been formed during a meiotic recombination in a human ancestor that deleted DNA from the telomeric region of a *KIR* haplotype to fuse the 5' part of a *3DL1* allele with the 3' part of a *3DL2* allele. Although the size of the deletion is uncertain because of gene-content variability, the most likely event would have involved the A haplotype configuration shown in Figure 1A with deletion of ~30 kb containing all of *2DS4* and parts of *3DL1* and *3DS1*. That the telomeric part of most chimpanzee *KIR* haplotypes has similarly, but independently, evolved to resemble that of the *KIR3DL1/2v*-containing haplotypes, points to this simplified structure having conferred advantage in at least two different circumstances.

Generation of *KIR3DL1/S1* diversity by interlineage recombination

Domain-by-domain phylogenetic analysis of 61 *3DL1/S1* alleles shows that a minimum of 12 (~20%) alleles arose through intragenic meiotic recombination (Fig. 2). Most of these events (nine) involved recombination between two of the three different *3DL1/S1* lineages: *3DL1-005*, *3DL1-015*, and *3DS1*. The two

Class I. The D1 and D2 domains form the ligand-binding site, and the D0 domain is an enhancer that modulates the strength of the ligand–receptor interaction (Khakoo et al. 2002).

Three 3DL1/S1 allotypes likely arose by meiotic gene conversion. Genomic sequence comparison indicates that 3DL1*009 was formed by conversion between 3DL1*001 and 3DS1*01301 that involved a sequence of 1.4–1.5 kb containing exons 2 and 3 (Fig. 2C; Supplemental Fig. S4). Consequently, 3DL1*009 combines the D0 domain from 3DS1*013 with the other domains from 3DL1*001. In analogous fashion, 3DL1*054 combines the D1 domain from 3DS1*013 with the other domains from 3DL1*002 (Thomas et al. 2008). The third candidate for gene conversion involves the arginine/histidine dimorphism at position 31 in the D0 domain. Uniquely, this dimorphism has been introduced into all three 3DL1/S1 lineages, through conversions involving a maximum of 70–110 bp of DNA (Fig. 2D). Residue 31 is part of a positively selected cluster of surface residues implicated in the enhancing function of the D0 domain (Khakoo et al. 2002). In contrast to these three products of interlineage gene conversion, 3DL1*042 combines the leader peptide and D0 domain from 3DS1*013 with the other domains from 3DL1*005 and was likely the product of a simple crossover between the two alleles (Fig. 2B). Similarly, 3DL1*001 and 3DL1*043 combine a D0 domain derived from the 3DL1-005 lineage with the other domains from the 015 lineage. Although the three lineages and their distinctive differences have been maintained by balancing selection

over several million years, we also see that these features have regularly been recombined to produce 3DL1/S1 allotypes with distinctive functions that presumably confer some selective advantage in the short term.

KIR3DL1/2v is an inhibitory receptor with distinctive specificity for Bw4 epitopes of HLA-A and -B

A characteristic of 3DL1/S1 gene expression is that each allele is expressed only by a fraction of NK cells, and the fraction varies with the allele (Gardiner et al. 2001; Chan et al. 2003; Trundley et al. 2007; Thomas et al. 2008). We therefore assessed cell surface expression of 3DL1/2v. The KIR3DL1-specific antibody, DX9, bound to a subset (17%) of peripheral blood NK cells from a donor heterozygous for 3DL1*059 and 3DL1*004. Because 3DL1*004 is not expressed at the cell surface (Pando et al. 2003), this DX9 binding had to be due to the expression of 3DL1*059 (Fig. 3A). Comparison of peripheral blood NK cells from different donors, and expressing different 3DL1 allotypes, showed that the level of DX9 binding to 3DL1*059 was intermediate between that observed for 3DL1*001 and 3DL1*005 (Fig. 3A). This binding hierarchy correlates with the two dimorphisms that distinguish the extracellular domains of the three allotypes. High-binding 3DL1*001 has proline 182 and tryptophan 283, whereas low-binding 3DL1*005 has serine 182 and leucine 283; 3DL1*059 is a hybrid of the two that combines proline 182 with leucine 283.

We next assessed the capacity of 3DL1/2v to function as an inhibitory receptor. To do this, we used an in vitro assay in which the NK cell line kills the HLA Class I-deficient 221 cell line. This killing can be inhibited if the NK cells are transduced with an inhibitory KIR and the 221 target cells are transfected with a complementary HLA Class I ligand (Gumperz et al. 1995). Transduction of the NK cell line with 3DL1*059 cDNA gave an NK cell for which 3DL1*059 (3DL1/2v) is the only KIR expressed at




Figure 2. Motif and domain shuffling between three lineages diversifies 3DL1/S1. (A) Shown to scale is the genomic organization of the 3DL1/S1 locus. (Boxes) Exons; exons 2–5 encode the three Ig domains, D0, D1, and D2. (Vertical arrows) The genomic regions and the number of recombination events detected from comparison of 3DL1/S1 alleles. (*) Recombination event that placed residue leucine 283 onto a different background allotype. (B) Schematic of 12 recombinant alleles of 3DL1/S1 that were identified using domain-by-domain phylogenetic analysis. The recombinant allotypes are represented by segments colored according to allelic lineage: (red) 015, (blue) 005, (green) 3DS1. The allotypes shown at the top of the panel are encoded by the most common modern alleles: 3DL1*01502, 3DL1*00501, and 3DS1*01301. For example, 3DL1*001 is identical to 3DL1*00501 in exons 1–3 and 3DL1*01501 in exons 4–9. (Gray) Recombination from another locus (3DL2); (pink) within-lineage recombinants. (White asterisk) Tryptophan–leucine substitution at residue 283; (black asterisk) recombination has replaced tryptophan at residue 283 with leucine; (‡) threonine 118 that distinguishes 3DL1*043 from 3DL1*001 and is shared with 3DL1*038. (C) The pairwise identity plot shows that 3DL1*009 formed by gene conversion. (Black line) Identity of 3DL1*009 with 3DL1*001; (green line) identity of 3DL1*009 with 3DS1*01301. The recombination included exons 2 and 3, which encode D0. (Across the top, vertical bars) SNP markers; (vertical arrows) the minimum and maximum limits of the gene conversion. Genomic sequences used for the RDP analysis include representatives of the three allelic lineages of 3DL1/S1 (listed in Methods). The 3DL1*009 cDNA sequence that was independently obtained (Middleton et al. 2007) corresponds precisely to the reading frame of the locus characterized here. (D) Shown for each of the 3DL1/S1 lineages is a pair of alleles that are dimorphic at (yellow) codon 31. Nucleotide differences in D0 are shown, and those that distinguish the three lineages are colored as in panel A. (Top) Amino acid substitutions with the ancestral residue first and the ancestral nucleotide immediately below. (Right panel) A homology model of D0; residue 31 (yellow) occurs in a patch of positively selected residues (orange) that were identified in Norman et al. (2007).

the cell surface. The specificity and function of 3DL1*059 were examined in cytotoxicity assays and compared to the 3DL1 and 3DL2 “parental” receptors. NKL cells expressing 3DL1*059, 3DL1*001, or 3DL1*01502 killed HLA Class I-deficient 221 cells as effectively as untransfected NKL cells. When transfected 221 cells expressing Bw4⁺ HLA-B*1513 were used as the target, reduced lysis was observed for NKL cells expressing 3DL1*059, 3DL1*001, or 3DL1*015, compared to lysis by NKL cells that express no KIR or KIR3DL2 that has no affinity for HLA-B*1513 (Fig. 3B, left). These inhibitory effects were abrogated by the inclusion of either anti-3DL1 (DX9) (Fig. 3B) or anti-HLA Class I (DX17) (data not shown) monoclonal antibodies, showing that the inhibition observed for the 3DL1-transduced NKL cells was dependent on the combination of 3DL1 on the NK cell and HLA-B*1513 on the target cell.

The inhibition mediated by the interaction of B*1513 with 3DL1*059 was comparable to that observed for 3DL1*001 and greater than that seen for 3DL1*015. Thus, the Bw4 epitope of HLA-B is demonstrated to serve as a ligand for 3DL1*059. Similar experiments showed that interaction of 3DL1*059 with the Bw4⁺ HLA-A*3201 allotype also inhibited the lysis of transfected 221 cells, to an extent comparable to 3DL1*015, but less than 3DL1*001 (Fig. 3B, center). In contrast, the Bw4⁻ HLA-A*1102 allotype did not engage 3DL1, but interacted with 3DL2*001 to inhibit the lysis of 221 cells (Fig. 3B, right), in a manner consistent with its HLA-A3, HLA-A11 specificity (Dohring et al. 1996; Pende et al. 1996; Hansasuta et al. 2004).

In summary, these results demonstrate that 3DL1*059 is a functional, inhibitory cell-surface receptor with a specificity for Bw4⁺ HLA Class I that is characteristic of KIR3DL1. The unusual 3DL2-like signaling domain of 3DL1*059 (Fig. 4) generates inhibitory signals that are within the range of those obtained from conventional 3DL1 signaling domains, but, as expected, does not skew the specificity of 3DL1*059 toward the HLA-A*1102 recognized by KIR3DL2. Distinguishing 3DL1*059 from the other 3DL1 allotypes examined here is the similar strength of the inhibition resulting from interactions with Bw4 epitopes on HLA-A and HLA-B “backgrounds” (Fig. 3B).

KIR3DL1/2v generates weaker inhibition than KIR3DL1

To examine further the effect of the 3DL2-like transmembrane region and cytoplasmic tail of 3DL1*059, we made a mutant (m1) in which they were replaced by the homologous domains of 3DL1*001. Reciprocally, a second mutant (m2) paired the extracellular domains of 3DL1*001 with the transmembrane region and cytoplasmic tail of 3DL1*059 (Fig. 3C, left). NKL transductants expressing these two mutants and their natural allotypes were compared in cytotoxicity assays against 221 target cells and 221 transfectants expressing A*3201 or B*1513. This analysis showed that the combination of 3DL1*059 and B*1513 gave a weaker inhibition than the combination of m1 and B*1513 (Fig. 3C, center). A similar trend was seen when the ligand was A*3201, but the difference was much smaller (Fig. 3C, right). For the reciprocal pair, 3DL1*001 gave a stronger inhibition than m2, a difference that was greater with A*3201 as the ligand than with B*1513. These results show that in all combinations, the trend is to weaker inhibition when the transmembrane region and cytoplasmic domain are derived from 3DL2. Thus another potential selective advantage of 3DL1/2v is its capacity to generate a weaker inhibitory signal than its progenitor 3DL1 allotype.

Because 3DL1*059 and m2 only differ at position 283, as do 3DL1*001 and m1, this mutational analysis also showed how the





Figure 3. 3DL1/2v mediates HLA-allotype specific inhibition of NK cells. (A) Binding of the 3DL1-specific monoclonal antibody DX9 to NK cells shows that 3DL1/2v is expressed at the cell surface at intermediate level. Shown are FACS analyses of peripheral-blood NK cells from donors who express single 3DL1 allotypes. (Right) The table shows amino acid differences that correspond to the 3DL1 expression level. 3DL1*004 is not expressed because of leucine-for-serine substitution at residue 86 (Pando et al. 2003). 3DL1*015 has further differences in D0 that are shown in Figure 1. Error bars indicate the standard deviation of DX9-PE fluorescence intensity, from all of the lymphocytes that stained positive with DX9. (B,C) Results from Cr⁵¹-release cytotoxicity assays. The basis for this assay is killing of HLA Class I-deficient cells (221) by an NK cell line (NKL). Inhibition of cytotoxicity occurs if NKL is transduced with inhibitory KIR and 721.221 is transfected with cognate HLA Class I ligand. Blocking the interaction with specific antibody restores target killing to that obtained using non-transduced NKL. The specificity of inhibition was determined in replicate assays using DX9, which specifically blocks 3DL1, or DX31, which specifically blocks 3DL2. The percent specific inhibition that is shown was calculated from killing in the presence of control/specific-blocking antibody. Results are mean (\pm SE) of five experiments at an effector:target ratio of 20:1. (***) $P < 0.001$; (**) $P < 0.01$ from Student's *t*-test for comparison of means. All of the effectors killed HLA-negative targets. Each of these assays shows different combinations of KIR and ligand. (B) The degree of inhibition mediated by natural KIR allotypes; these are 3DL1*001, 3DL1*015, 3DL1/2v (3DL1*059), and 3DL2*001 or no KIR (nkl). Target cells were 721.221 cells transfected with (left) HLA-B*1513, (center) A*3201, and (right) A*1102. B*1513 and -A*3201 are ligands for 3DL1, and A*1102 is a ligand for 3DL2. (C, left) The table shows the composition of the mutant KIR allotypes. Tail-swap mutant m1 (*001-L283) has the 3DL1*059 Ig-domain with a 3DL1*001 tail. m2 (*059-W283) has the 3DL1*001 Ig-domain with a 3DL2*001 tail. Results of the cytotoxicity analysis are shown for (center) HLA-A*3201 and (right) HLA-B*1513.

dimorphism at position 283 affects 3DL1 function. Substitution of tryptophan for leucine at position 283 increased the inhibitory signal on binding to A*3201 but decreased the response to B*1513 (Fig. 3C). For 3DL1*059, the trend was similar—tryptophan 283 favored interaction with A*3201, leucine 283 its interaction with B*1513—but the difference was smaller. Thus a potential advantage of the recombinations that change residue 283 is that they

through somatic recombination and mutation, NK cell receptors can only diversify through meiotic mutation and recombination. And in general, immune system genes have become more diversified by meiotic recombination than other functional types of human gene (Redon et al. 2006; Frazer et al. 2007) and display greater variation as assessed by copy number and segmental insertion/deletions (Dumas et al. 2007; Korb et al. 2007).



The state of the killer cell immunoglobulin-like receptor (*KIR*) locus in the leukocyte receptor complex (*LRC*) varies dramatically between species. In some, like the seals, it is a single conserved and nonpolymorphic gene, and in others, such as the dog, it appears to have been deleted (Hammond et al. 2009). In contrast, in the higher primates, the *KIR* locus has evolved to become a diverse multigene family encoding MHC Class I receptors (Khakoo et al. 2000; Rajalingam et al. 2004; Sambrook et al. 2005; Guethlein et al. 2007). On the basis of current information, *KIR* diversity appears greatest in the human species, where the combined effects of gene-content diversity and allelic polymorphism are such that unrelated individuals have distinct *KIR* genotypes (Shilling et al. 2002). The extent of *KIR* genotype variability approaches that of *HLA* class I, with the functionally important combination of *KIR* and *HLA* genotypes being even more diverse (Parham 2005). Unequal crossing over is the likely mechanism that expanded the primate *KIR* locus from its origin as a single-copy gene, and it is clearly implicated in the diversification of gene content in the modern human *KIR* haplotypes (Khakoo et al. 2000; Wilson et al. 2000; Martin et al. 2003). Further diversity is generated by homologous recombination, in particular, by the reassortment of allelic and gene-content motifs in the centromeric and telomeric parts of the locus (Wilson et al. 2000; Norman et al. 2004; Parham 2005). Here we have explored the role that meiotic recombination has played in the diversification of an individual human *KIR* gene, *KIR3DL1/S1*. This gene encodes highly polymorphic NK cell receptors that recognize HLA-A and HLA-B, the most polymorphic MHC genes.

Balancing selection and coevolution with HLA are consistently recognized features of the *KIR* (Hiby et al. 2004; Norman et al. 2004; Gendzekhadze et al. 2006; Single et al. 2007; Yawata et al. 2008). One of the strongest indicators for balancing selection is the long-term preservation of alleles without fixation or loss (Kimura and Ota 1969); another is the retention of alleles through periods of restricted population size. The *3DL1/S1* locus comprises three ancient lineages of alleles that have been maintained by balancing selection over more than 3 million years and are present in all modern human populations (Norman et al. 2007), despite severe bottlenecks for some (Hey 2005). Contrasting with the conservation of the *3DS1* lineage, the *3DL1-005* and *3DL1-015*

Figure 5. Simultaneous detection of *KIR3DL1/S1* polymorphism and copy-number using pyrosequencing. (A, top) The diploid sequence of a 17-bp fragment of exon 3 from an individual heterozygous for *3DL1*01502* and *3DS1*01301*. (Gray) SNP *g336a*. Underneath is a pyrogram obtained from the same individual. To generate the pyrogram, nucleotides were added to a single-strand template in the sequence shown, 1–11, and correspond to peaks of the same number. The peak height is proportional to the quantity of nucleotides that were incorporated, as shown by peak 1 (the sequence is *gg*), which is twice the height of peak 6 (*g*). Each peak is a sum of the haplotypes present, so that the monomorphic positions (relative peak height = 1) are used for calibration. The combined peak height at the heterozygous position shown (peaks 10 + 11) is equal to the peak from a single monomorphic position. Shown are four different pyrograms; (top left of each diagram) the derived genotype; (brackets) the peak-height ratio compared with the single monomorphic peak. (A) At SNP *g336a*, there is one peak for *g* and one for *a* (peaks 10 and 11), and each peak is half the height of a single peak (peak 6). This individual has one copy of *3DL1*01502* and one copy of *3DS1*01301* (0.5*g*: 0.5*a*). (B) At SNP *g336a*, there is one peak for *g* (peak 10) that is the same height as a single monomorphic position (peak 6) and no peak on addition of nucleotide *a*-11. This individual is homozygous, having two copies of *3DL1*01502* (1*g*: 0*a*). (C) There are two peaks as for A, but *g* is twice the height of *a* (0.67*g*: 0.33*a*), and their sum is the same as peak 6. This individual has two copies of *3DL1*01502* and one *3DS1*01301*. (D) This individual has one copy of *3DL1*01502* and two of *3DS1*01301* (0.33*g*: 0.67*a*).




Figure 6. Duplicating *KIR* loci diversifies the NK cell repertoire in quantity and quality. (A) Schematic of the donor haplotypes and duplication haplotype. (Across the top) The *KIR* loci; (shaded boxes) indicate presence of the locus. The donor *KIR* haplotypes B (black) and A (orange); the composite duplication haplotype D is colored accordingly. (Dotted line) Non-allelic homologous recombination that was mediated by sequence similarity in the 5'-regions of *3DP1* and *2DL5A* (Martin et al. 2003; Gomez-Lozano et al. 2005). (B) The seven different *2DL4*, *3DL1*, and *3DL2* haplotypes deduced from analysis of 80 individuals who have the duplication, and their haplotype frequencies in the populations where they were detected. The number of haplotypes analyzed from each population is indicated in parentheses. Georgia is the country. The Piramalai Kallar and the Yadheva are two distinct populations from Tamil Nadu in Southern India. (C) Shown are FACS analyses of freshly isolated *3DL1/S1*-expressing NK cells from a European family with a duplicate haplotype. (At the top of each plot) The pyrosequencing genotype. Son 1 inherited *3DS1*013* and *3DL1*002* (haplotype 3, panel B) from the mother and *3DS1*013* from the father. Monoclonal antibody Z27 discriminates *3DL1/S1* allotypes, having high (*3DL1*002* and *3DL1*015*), low (*3DL1*005* and *3DL1*007*), and very low (*3DS1*013*) staining patterns. Showing that *3DL1/S1* expression depends on the number of copies of *3DS1* present, Son 1 has twice the number of *3DS1*⁺ NK cells as the mother or father. Son 2 has inherited the opposite pair of haplotypes to Son 1, and expresses two distinct populations of high (**015*) and low (**007*) *3DL1* staining and no *3DS1*. Further differences among allotypes are quantitative, with **015* being expressed by more cells than **002* (Chan et al. 2003), as observed here by comparing *3DL1* expression of the mother and Son 1. (D) Three unrelated individuals chosen for their *3DL1/S1* genotype. (Left) An individual heterozygous for *3DL1*015* and *3DL1*005* is shown as a negative control for the very low-staining *3DS1*013* peak. (Center and right) Two individuals who both express all three lineages of *3DL1/S1* receptors; these FACS analyses are from NK cells that had been stored frozen. A comparison of fresh and frozen NK cell staining is shown in Supplemental Figure S6.

lineages of inhibitory receptors are now highly diverse. Of the approximately 60 alleles defined, 12 are recombinants, most of which have been formed by recombination or conversion between alleles from different lineages. Two main targets for recombination have been polymorphic motifs in the D0 domain, the enhancer that modulates the strength of the binding site formed by the D1 and D2 domains (Khakoo et al. 2002) and a dimorphism at position 283 in D2 that we show alters the strength of the inhibitory signal transduced upon binding of *3DL1* to Bw4.

Only the three lineage-defining *3DL1/S1* alleles—*3DS1*01301*, *3DL1*00501*, and *3DL1*01502*—are common to all human populations, the vast majority of the others being specific to particular populations, geographical regions, and ethnic groups (Norman et al. 2007). Since humans originated in Africa and eventually went on to populate other continents (Goldstein and Chikhi 2002), unequal crossing over has produced novel recombinant alleles and haplotypes that mark particular populations. For example, the *3DL1*009* recombinant allotype, in which the D0 domain of *3DL1*015* is replaced with that of *3DS1*013*, is restricted to European and some South Asian populations (Middleton et al. 2007; Norman et al. 2007). That we consistently observe population stratification of *3DL1/S1* alleles points to recent or ongoing selection for variation. Up to 10% of sub-Saharan African populations have a *KIR* haplotype that was formed within 0.74 million years by an unequal crossing over that caused the deletion of >30 kb from the telomeric part of the *KIR* locus and created a novel hybrid gene, by fusing exons 1–5 from *3DL1*005* with exons 7–9 of the *3DL2*001* gene. The fusion protein encoded by this *3DL1/2v* allele (*3DL1*059*) combines the extracellular, Ig-like domains of *3DL1*005* with the transmembrane and cytoplasmic domains of *3DL2*001*. As expected, *3DL1*059* has specificity for Bw4, but it has a more even response to HLA-A and HLA-B allotypes having the Bw4 epitope, and transduces a weaker inhibitory signal, than other *3DL1* allotypes. Since the formation of *3DL1*059* by recombination, subsequent point substitutions in the cytoplasmic tail produced *3DL1*060* and *3DL1*061* allotypes. Valine 384 that distinguishes *3DL1*061* is close to an ITIM motif (Feng et al. 2005), and the substitution of cysteine for serine at

residue 394 in 3DL1*060 that eliminates a protein kinase C phosphorylation site is predicted to increase inhibitory signals (Alvarez-Arias and Campbell 2007). Thus, the variants of 3DL1/2v have the potential for functional difference. That all hominoid *KIR* haplotypes have a lineage II gene with an exon 9 orthologous to that of 3DL2, despite much recombination, points to the importance of the signaling domain it encodes (Rajalingam et al. 2001; Sambrook et al. 2005; Guethlein et al. 2007).

Gene fusion is a recognized means for generating genetic novelty (Bailey and Eichler 2006), but to our knowledge, 3DL1/2v is the first demonstration of the phenomenon occurring in humans. Among the 600 gene fusions described for eukaryotes (Kummerfeld and Teichmann 2005), all those identified as human-specific are associated with disease or abnormality. One possible exception is the family of X chromosome gene fusions of *OPN1MW/LW* that cause anomalous color detection in males (Nathans et al. 1986), but may benefit female carriers (Deeb 2006). As shown for other SNPs at these loci, heterozygous females have enhanced color discrimination (Jameson et al. 2001).

Whereas the unequal crossing over that produced 3DL1/2v reduced the size of a *KIR* haplotype, in Eurasia a different event of unequal crossing over served to duplicate the 3DL1/S1 locus such that the haplotype had one copy of 3DS1 and one copy of 3DL1. Subsequent events of reciprocal crossing over have diversified this duplicated haplotype so that at least seven different 3DL1 alleles, including most of the more common alleles of both the 005 and 015 lineages, are associated with 3DS1*013. Although we do not know which 3DL1 allele was present on the original duplicated haplotype, that containing 3DL1*01502 appears the most prevalent.

When first characterized from cDNA, 3DL1 and 3DS1 were assigned to different loci based on the divergent sequence and function of their transmembrane and cytoplasmic domains (Robinson et al. 2006). Subsequent family and population studies showed that 3DL1 and 3DS1 usually segregate as alleles (Middleton et al. 2007), and sequence comparison indicated that 3DS1 was formed from 3DL1 by recombination with a gene encoding an activating *KIR* (Rajalingam et al. 2004). Consequently, 3DS1 and 3DL1 are generally considered to be alleles of a single locus: 3DL1/S1. The duplicated haplotypes are exceptional because they have two genes of which one is always 3DS1 and the other is always 3DL1. So far no duplicated haplotype containing two copies of 3DL1 and only one with two copies of 3DS1 (Gomez-Lozano et al. 2005) have been identified, indicating that such recombination is rare or that such events are selected against. Thus within the context of the duplicated haplotypes 3DS1 and 3DL1 are two different genes. This illustrates a more general complexity of the *KIR* system, namely, imprecision or blurring in the distinction between loci and alleles. At the *KIR*, *MHC*, and other immunological loci, an understanding of the synergy between allelic polymorphism and copy-number variability that generates diversity has required intensive, focused analysis (Bergstrom et al. 1999; Chung et al. 2002; Hollox et al. 2008). To determine the extent to which the findings apply to other gene families will require analyses of similar commitment and intensity (Dumas et al. 2007; Perry et al. 2008).

Throughout human history, balancing selection has maintained the 3DS1, 3DL1-005, and 3DL1-015 lineages of alleles. Today, the only three *KIR3DL1/S1* alleles present in all the populations studied are 3DS1*01301, 3DL1*00501, and 3DL1*01502. This observation indicates that the three lineages have distinct and complementary functions that have facilitated the survival

and propagation of human populations, a corollary being that populations that lost a 3DL1/S1 lineage failed to compete and survive over the long term. Despite the benefit of three allelic lineages for populations, most modern humans carry alleles from only one or two 3DL1/S1 lineages and suffer no obvious disadvantage in either survival or reproduction. In this context, the potential advantage of the duplicated *KIR* haplotype is that it is a mechanism by which individuals can carry all three 3DL1/S1 lineages and, as we have shown, express them as NK cell receptors. In sub-Saharan African populations, the balance between the three 3DL1/S1 lineages appears to have given way to selection for the 3DL1-015 lineage and against the 3DS1 and 3DL1-005 lineages (Norman et al. 2007). A further characteristic of sub-Saharan Africans is that a significant proportion of the 3DL1-005 lineage allotypes is 3DL1*059, 3DL1*060, and 3DL1*061, products of the gene fusion between 3DL1*005 and 3DL2. Selection for these alleles, might also reflect selection against conventional 3DL1*005 and for the modified functions imposed on its extracellular domains by the distinctive transmembrane and cytoplasmic domains of 3DL2.

KIR3DL1 and 3DL2 that recognize determinants of HLA-A and -B are encoded by lineage II *KIR* genes, which are represented in hominoid species by two or more genes. Exceptional is the chimpanzee, which has one lineage II *KIR* gene (*Pt-KIR3DL1/2*) that encodes a protein with structural and functional similarities to both 3DL1 and 3DL2. In chimpanzee *KIR* haplotypes, *Pt-KIR3DL1/2* is the only gene on the telomeric side of *Pt-KIR2DL4*, an arrangement like that of the human haplotypes containing 3DL1/2v (3DL1*059, 3DL1*060, and 3DL1*061) in which 3DL1 and 3DL2 have been reduced to a single fusion gene. We have shown that the similarities of 3DL1/2v and *Pt-KIR3DL1/2* are not due to common ancestry but to convergence, further emphasizing the dynamic nature of the *KIR* gene family and continuing cycles of gene expansion and contraction through meiotic recombination.

Methods

Subjects

The subjects studied here are as described by Norman et al. (2007). Blood samples were collected and the research conducted with approval from the appropriate Institutional Review Boards. The two Tanzanian populations are from (1) a village that lives on the coastal plain near the Indian Ocean and (2) a village at an altitude of 1700 m in the West Usambara Mountains.

KIR nomenclature

KIR genes and alleles were named by the *KIR* Nomenclature Committee (Marsh et al. 2003), formed from the WHO Nomenclature Committee for factors of the HLA system and the HUGO Genome Nomenclature Committee. A curated database is available at <http://www.ebi.ac.uk/ipd/kir/> (Robinson et al. 2006). <D> denotes the number of Ig-like Domains; <L> a Long, inhibitory, cytoplasmic tail; <S> a Short, activating, tail; and <P> a Pseudogene. For each locus, the alleles are named in the order of their discovery, with the first three digits distinguishing alleles encoding different proteins. The second two digits are used to indicate synonymous variation. As an example, *KIR3DL1*01501* and *KIR3DL1*01502* are synonymous variants of the 3DL1*015 allele, and both encode the 3DL1*015 allotype—an inhibitory receptor having three Ig-like domains. When the meaning is unambiguous, *KIR* or even *KIR3DL1* can be dropped from allele names.

PCR/DNA sequencing

PCR was performed using a Perkin-Elmer 9600 thermal cycler with a 3-min denaturing step at 94°C, 10 cycles of (10 sec at 94°C; 60 sec at 65°C) and 20 cycles of (10 sec at 94°C, 50 sec at 61°C, 30 sec at 72°C). When the expected amplicons were >3.5 kb, long range-PCR (LR-PCR) was performed using TripleMaster/HiFi reagents (Eppendorf) and the oligonucleotide primers described in Supplemental Figure S2. LR-PCR conditions were 3 min at 94°C followed by 28 cycles of (20 sec at 94°C, 10 sec at 61°C, 4 min at 68°C) completed with 15-min extension at 68°C. Products were cloned using the pCR 2.1-TOPO vector (Invitrogen) and sequenced using internal primers. Standard DNA sequencing was performed in forward and reverse directions using BigDye Terminator v3.1 and analyzed using an ABI-377 sequencer (ABI). Three clones of the desired allele were sequenced from each individual.

Characterizing the *KIR3DL1/2v* gene sequence

The *KIR3DL1/2v* gene sequence was characterized from one donor using multiple PCR primer pairs (Supplemental Fig. S7) and from four donors using six overlapping PCR fragments that spanned the haplotype from *2DL4* to *FCAR* (Supplemental Fig. S2). The four donors were selected to represent all three different *3DL1/2v* sequences and also to have a distinct second *KIR* haplotype. Unambiguous sequence data were generated from one of the donors, who is hemizygous for *3DL1/2v* so has no second *3DL1/S1* allele (Supplemental Fig. S2). For each heterozygous individual, sufficient SNPs were present to distinguish two haplotypes upon cloning, except for two of the reactions that were allele-specific (bands A and C) (Supplemental Fig. S2). Each amplicon was cloned using pCR 2.1 and sequenced in triplicate for each allele present. All of the PCR primers were designed to be *KIR* gene- or allele-specific (Supplemental Fig. S2; Supplemental Table S1). Accession numbers for the newly generated *3DL1*059-61* genomic DNA sequences are EU267269–71 and FJ459734.

The *3DL1/S1*059* donor was an African-American from California (genotype: *3DL1*031*, *3DL1*059*, *3DL2*001*). The *3DL1/S1*060* donor was an African from Nigeria (genotype: *3DL1*035*, *3DL1*60*, *3DL2*001*). The *3DL1/S1*061* donor was an African-American from California (genotype: *3DL1*040*, *3DL1*061*, *3DL2*010*). The hemizygous donor was an African from Nigeria who has a *KIR* haplotype that lacks *3DP1*, *2DL4*, and *3DL1/S1* but retains *3DL2* (Norman et al. 2004). This individual has one *3DL1/S1* allele and one *3DL2* allele (genotype: *3DL1*059*, *3DL2*006*).

DNA sequences and recombination analysis

Recombinant sequences were identified from a domain-by-domain phylogenetic analysis. Gene conversion was identified using RDP (Recombination Detection Programs) version 2 (Martin et al. 2005) with a sliding window of 20 bp, with Bonferroni correction and a threshold of $P=0.001$. Coding sequences of *3DL1/S1* used for alignments were obtained from the IPD database (<http://www.ebi.ac.uk/ipd/kir/index.html>) (Robinson et al. 2006) and those described in Belle et al. (2008) and Thomas et al. (2008). cDNA from *3DS1*050* (EF582383) was fully characterized here using methods previously described (Shilling et al. 2002). Genomic DNA sequences that spanned exons 1–5 (encoding the extracellular domains) and exons 7–9 (encoding the cytoplasmic domain) were characterized by LR-PCR from the following alleles: *3DL1*001*, *3DL1*00501*, *3DL1*009*, *3DL1*01501*, *3DL1*022*, *3DL1*029*, *3DL1*030*, *3DL1*031*, *3DL1*035*, *3DL1*036*, and *3DL1*040* (GenBank: FJ158650–60). *3DS1*01301* and *3DL2*007* sequences were extracted from AL133414 (*3DS1a*) (Wilson et al. 2000) and AY320039 (*3DS1b*). A second *3DL1*001* genomic

sequence, and *2DL4*00801* and *3DL2*001* were obtained from AC011501 (Wilson et al. 2000). For the analysis indicated in Supplemental Figure 3B, a further 2 kb of sequence that surrounds the crossover point in intron 5 was obtained from *3DL1*00501*, *3DL1*01501*, and *3DL1*040*; for *3DL1*002* the equivalent sequence was obtained from CU151839 and *3DL2*010* from CU464063 (Horton et al. 2006). *pt2DL4* and *pt3DL1/2* genomic DNA sequence was obtained from BX842589 (Sambrook et al. 2005) and *Popy2DL4* and *Popy3DL1a* from EF014479 (Guethlein et al. 2007).

DNA sequence analysis

Nucleotide sequences were aligned using ClustalX (Thompson et al. 1997) and BioEdit (www.mbio.ncsu.edu/BioEdit/bioedit.html). Neighbor-joining phylogenetic analyses were conducted using the Tamura-Nei method of MEGA3.1 and 500 bootstrap replicates (Kumar et al. 2004). PAML was used to reconstruct the ancestral sequences at specified nodes, using the marginal reconstruction method and the M8 model (Yang 2007).

Divergence time estimations

Divergence times were estimated using the MCMCTREE program from PAML 4 (Yang 2007), which uses Markov-chain Monte Carlo analysis for estimating mean posterior divergence times and their 95% credibility interval (CI). The Markov chain was sampled 5000 times every 10 cycles, and the burn-in stage was set to 5000 cycles. MODELTEST 3.7 (Posada and Crandall 1998) was used to gauge the nucleotide-substitution model (HKY95) and the α -distribution of this substitution (0.83 and 1.03 for the sequences 5' and 3' from the *3DL1/2v* crossover, respectively). Calibration points were set according to fossil data and the divergence times: CI = 23–33 Mya for macaque/hominoid, CI = 10–18 Mya (mean 12) orangutan/hominid, and CI = 6–8 Mya (mean 7) for chimpanzee/hominid (Benton and Donoghue 2007).

Genotyping by pyrosequencing

Using primers described in Supplemental Table 1, individual exons from *2DL4* and *3DL2* were amplified and subjected to pyrosequencing. Exon-specific PCR was performed using a Perkin-Elmer 9600 thermal cycler with a 3-min denaturing step at 94°C, 10 cycles of (10 sec at 94°C, 60 sec at 65°C), and 20 cycles of (10 sec at 94°C, 50 sec at 61°C, 30 sec at 72°C). Identical conditions were used for a second specific reaction but with 35 cycles in the final step. Samples were purified using streptavidin-coated Sephadex beads, and pyrosequencing reactions were performed using the Pyro-Gold reagents and a PSQ96A machine fitted with Capillary Dispensing Tips (Biotage Ltd.). *3DL1/S1* genotyping was performed as described (Norman et al. 2007). The genotyping procedures were performed in parallel with previously described family and control samples (Gardiner et al. 2001; Shilling et al. 2002; Artavanis-Tsakonas et al. 2003; Norman et al. 2004, 2007). To further validate the techniques, a random selection of 25% donors was also re-sequenced from a freshly generated amplicon. According to the most recent sequence alignments (<http://www.ebi.ac.uk/ipd/kir/index.html>), the combination of techniques discriminates 11 *2DL4* alleles, 52 *3DL1/S1* alleles, 22 *3DL2* alleles, three *3DL1/2v* alleles, and copy-number variation for each locus.

Detection of *KIR3DL1/2v* by genotyping *3DL1/S1* and *3DL2*

Because no SNP uniquely defines the *3DL1/2v* sequences, the pyrosequencing protocol was designed to detect a unique

combination of SNPs in exons 1–5 that distinguishes *3DL1/2v* from *3DL1/S1* (Fig. 1). Three different *3DL1/2v* alleles (*3DL1*059*, *3DL1*060*, *3DL1*061*) were distinguished by one further SNP in exon 5 and two SNPs in exon 9. At the cDNA level, *3DL1*059* (Shilling et al. 2002) and *3DL1*060* (Artavanis-Tsakonas et al. 2003) have been described previously, and *3DL1*061* was discovered during the present study. Two other *3DL1/2v* sequences reported previously (AY366254-5) were not observed in the present study. Heterozygosity was calculated using Arlequin (Schneider et al. 2000).

Detecting copy-number variation using pyrosequencing

Pyrosequencing uses enzyme-coupled reactions to generate light from the pyrophosphate molecules released upon DNA elongation (Ronaghi et al. 1996). Nucleotides are added sequentially so that the reaction proceeds only when the correct base is added. Light emission is plotted on a Pyrogram that has peak height proportional to the number of pyrophosphate molecules released. The technique is semiquantitative because the combined peak heights from a polymorphic position equal the height of the single peak at a monomorphic position (Fig. 5). With this method, we were able to determine the presence of three *3DL1/S1* alleles in individuals having a duplication of the *3DL1/S1* locus on one haplotype even when two of the alleles were identical in sequence, because peak-height ratios were 2:1 in favor of the allele present in two copies. All genotyping methods were designed so that each genotype gave a distinct pattern of several SNPs dispersed through the locus and did not rely on single marker SNPs. We were thus able to accurately assign three-copy genotypes by virtue of consistency in peak-height ratios throughout the locus.

To validate the copy-number detection method, two families shown previously by segregation analysis to have duplicated *3DL1/S1* (Martin et al. 2003; Norman et al. 2004) were used as standards. Furthermore, for eight of the 80 individuals in whom the duplication was detected, PCR products that span exons 3–5 of *2DL4* were generated, cloned, and sequenced (12 clones) to verify the presence of three different *2DL4* alleles and thus of the duplication. Some individuals may possess two copies of a *3DL1/S1*-duplicated haplotype, and if the *3DL1/S1* pairs on the two haplotypes were identical, we would not have distinguished them from a normal heterozygote. However, the observed maximum frequency of 10% for duplicated-*3DL1/S1* haplotypes implies that, assuming Hardy-Weinberg equilibrium, only one or two individuals from the entire cohort had two identical duplicated-*3DL1/S1* haplotypes.

Haplotype composition and frequency were estimated in the following way: Allele phase was assigned per population by linkage disequilibrium using Arlequin (Schneider et al. 2000). Genotypes found in only one or two individuals were first compared with other populations of similar origin, and then with the entire sample set, to derive the most parsimonious interpretation. This approach was designed to estimate the minimum number of different haplotypes that could be distinguished based on the composition of *2DL4*, *3DL1/S1*, and *3DL2* alleles. After such iterative deductions, the genotypes of only two individuals remained ambiguous. Fifty-one of the 80 individuals having a duplication haplotype were genotyped using locus-specific primers to determine their *KIR* locus genotype (Uhrberg et al. 1997).

Flow cytometry

Peripheral blood mononuclear cells (PBMC) were isolated on ficoll gradients. Monoclonal antibodies used for flow cytometry were CD3-PE-Cy5, CD56-FITC, 3DL1(DX9)-PE, and IgG1 isotype con-

trols (all BD Biosciences) and 3DL1(Z27)-PE (Beckman Coulter). CD3[−]CD56⁺ NK cells were monitored for expression of 3DL1/S1 using DX9, which reacts with 3DL1, and Z27, which reacts with both 3DL1 and 3DS1 (Supplemental Fig. S6; Gardiner et al. 2001; Carr et al. 2007; Trundley et al. 2007; Thomas et al. 2008). Thus, NK cells from individuals carrying *3DS1* and *3DL1* give two peaks of Z27 staining, but only one peak of DX9 staining. 3DL1*004 is not expressed at the cell surface and binds neither antibody (Pando et al. 2003). Flow-cytometry data were analyzed using FlowJo software.

Generation of NK effector and target cell lines

Effector cells were NKL cells transduced to express wild-type and mutant 3DL1 allotypes. Full-length *KIR* cDNA sequences were amplified from PMBC and cloned into a pCR 2.1 vector (Invitrogen). Site-directed mutagenesis was performed using the QuikChange mutagenesis kit (Stratagene) according to the manufacturer's instructions. Full-length coding regions were then cloned into the pBMN retroviral vector and transferred by retrovirus to NKL cells. Recombinant retrovirus was generated by transfection into Phi-NX cells, supernatants were used to infect NKL, and the cells were sorted for KIR expression level using a FACS Vantage cell sorter (BD Biosciences), as previously described (Moesta et al. 2008).

Target cells were the Class I-deficient B-cell line 221 and transfectants of 221 expressing HLA allotypes: A*1102, A*3201, or B*1513. A*3201 cDNA was obtained from the WT47 cell line. A*1102 cDNA was generated by site-directed mutagenesis of A*1101 cDNA, which had been obtained from the KT17 cell line. HLA-E can present peptides that are derived from the leader peptides of HLA Class I molecules and protect 221 cells from lysis, owing to interaction of HLA-E/peptide with the CD94/NKG2A inhibitory receptor that is expressed by NK cells (Braud et al. 1998). Recombinant PCR was used to replace the HLA-A leader peptide fragment with VMAPVTLLLLL; the R5V mutation (underlined) abrogates interaction of the HLA-E/peptide with CD94/NKG2A (Michaelsson et al. 2002). HLA Class I cDNA was transfected into 221 cells using pBjneo as previously described (Gumperz et al. 1995).

NK cytotoxicity assays

Standard chromium-release assays were used to assess the degree of inhibition conferred by specific 3DL1 allotypes. NKL cells expressing 3DL2*001 and 721.221 cells expressing HLA-A*1102 were used as controls to investigate the specificity of 3DL1/2v-mediated inhibition. Two blocking agents were used in parallel experiments as controls: DX9 (anti-3DL1) was used to block the 3DL1/HLA interaction, and DX31 (anti-3DL2) was used to block the 3DL2/HLA-A11 interaction. Effector cells were mixed with ⁵¹Cr loaded target cells for 4 h at 37°C at ratios ranging from 40:1 to 10:1. Following incubation, supernatants were harvested and ⁵¹Cr was quantified using a Wallac β-scintillation counter. Percent specific lysis was calculated using the formula [(Specific Release – Spontaneous Release)/(Total Release – Spontaneous Release) × 100]. Experiments were conducted in triplicate for each condition, and each experiment was repeated independently five times. Comparison of means at the 20:1 ratio was performed using the Student's *t*-test (8 df).

Complete list of author affiliations

¹Department of Structural Biology and Department of Microbiology and Immunology, Stanford University School of Medicine,

Stanford, California 94305, USA; ²Department of Preclinical Sciences, Faculty of Medical Sciences, University of West Indies, St. Augustine, Trinidad and Tobago; ³Department of Transfusion Medicine, Faculty of Medicine and Siriraj Hospital, Mahidol University, Bangkok 10070, Thailand; ⁴School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan; ⁵Immunology Service, Hospital Universitari Son Dureta, Palma 07014, Spain; ⁶Istanbul Medical Faculty, Department of Physiology, Istanbul University, Istanbul 34093, Turkey; ⁷Department of Medicine, Aga Khan University Hospital, Karachi 74800, Pakistan; ⁸Department of Clinical Immunology, REA Centre, Tbilisi 0160, Georgia; ⁹Noguchi Memorial Institute for Medical Research, University of Ghana, Legon LG581, Ghana; ¹⁰Centre of Experimental Medicine "Miguel Layrisse" Venezuelan Research Institute (IVIC), Caracas 21827, Venezuela; ¹¹Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea; ¹²Centre for Advanced Studies in Functional Genomics, School of Biological Sciences, Madurai Kamaraj University Madurai 625-021, India; ¹³Hung Kuang University, Taichung 433, Taiwan; ¹⁴Centre for Nephrology and The Anthony Nolan Trust, Royal Free and University College Medical School, London NW3 2QG, United Kingdom; ¹⁵Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; ¹⁶Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA; ¹⁷Moorfields Eye Hospital, London EC1V 2PD, United Kingdom; ¹⁸Clinical Transplantation Laboratory, Guy's and St. Thomas' Foundation Trust and King's College, London SE1 9RT, United Kingdom; ¹⁹Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California 94304, USA; ²⁰Immune Disease Institute, Boston, Massachusetts 02115, USA

Acknowledgments

We thank Lewis Lanier for supplying the DX17 and DX31 antibodies.

References

- Alvarez-Arias, D.A. and Campbell, K.S. 2007. Protein kinase C regulates expression and function of inhibitory killer cell Ig-like receptors in NK cells. *J. Immunol.* **179**: 5281–5290.
- Artavanis-Tsakonas, K., Eleme, K., McQueen, K.L., Cheng, N.W., Parham, P., Davis, D.M., and Riley, E.M. 2003. Activation of a subset of human NK cells upon contact with *Plasmodium falciparum*-infected erythrocytes. *J. Immunol.* **171**: 5396–5405.
- Bailey, J.A. and Eichler, E.E. 2006. Primate segmental duplications: Crucibles of evolution, diversity and disease. *Nat. Rev. Genet.* **7**: 552–564.
- Bashirova, A.A., Martin, M.P., McVicar, D.W., and Carrington, M. 2006. The killer immunoglobulin-like receptor gene cluster: Tuning the genome for defense. *Annu. Rev. Genomics Hum. Genet.* **7**: 277–300.
- Belle, I., Hou, L., Chen, M., Steiner, N.K., Ng, J., and Hurley, C.K. 2008. Investigation of killer cell immunoglobulin-like receptor gene diversity in KIR3DL1 and KIR3DS1 in a transplant population. *Tissue Antigens* **71**: 434–439.
- Benton, M.J. and Donoghue, P.C. 2007. Paleontological evidence to date the tree of life. *Mol. Biol. Evol.* **24**: 26–53.
- Bergstrom, T.F., Erlandsson, R., Engkvist, H., Josefsson, A., Erlich, H.A., and Gyllenstein, U. 1999. Phylogenetic history of hominoid DRB loci and alleles inferred from intron sequences. *Immunol. Rev.* **167**: 351–365.
- Boyington, J.C., Brooks, A.G., and Sun, P.D. 2001. Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. *Immunol. Rev.* **181**: 66–78.
- Braud, V.M., Allan, D.S., O'Callaghan, C.A., Soderstrom, K., D'Andrea, A., Ogg, G.S., Lazetic, S., Young, N.T., Bell, J.L., Phillips, J.H., et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. *Nature* **391**: 795–799.
- Campbell, M.C. and Tishkoff, S.A. 2008. African genetic diversity: Implications for human demographic history, modern human origins, and complex disease mapping. *Annu. Rev. Genomics Hum. Genet.* **9**: 403–433.
- Carr, W.H., Rosen, D.B., Arase, H., Nixon, D.F., Michaelsson, J., and Lanier, L.L. 2007. Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. *J. Immunol.* **178**: 647–651.
- Cella, M., Longo, A., Ferrara, G.B., Strominger, J.L., and Colonna, M. 1994. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. *J. Exp. Med.* **180**: 1235–1242.
- Chan, H.W., Kurago, Z.B., Stewart, C.A., Wilson, M.J., Martin, M.P., Mace, B.E., Carrington, M., Trowsdale, J., and Lutz, C.T. 2003. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. *J. Exp. Med.* **197**: 245–255.
- Chung, E.K., Yang, Y., Rennebohm, R.M., Lokki, M.L., Higgins, G.C., Jones, K.N., Zhou, B., Blanchong, C.A., and Yu, C.Y. 2002. Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex. *Am. J. Hum. Genet.* **71**: 823–837.
- Deeb, S.S. 2006. Genetics of variation in human color vision and the retinal cone mosaic. *Curr. Opin. Genet. Dev.* **16**: 301–307.
- Dohring, C., Scheidegger, D., Samaridis, J., Cella, M., and Colonna, M. 1996. A human killer inhibitory receptor specific for HLA-A1,2. *J. Immunol.* **156**: 3098–3101.
- Dumas, L., Kim, Y.H., Karimpour-Fard, A., Cox, M., Hopkins, J., Pollack, J.R., and Sikela, J.M. 2007. Gene copy number variation spanning 60 million years of human and primate evolution. *Genome Res.* **17**: 1266–1277.
- Feng, J., Garrity, D., Call, M.E., Moffett, H., and Wucherpfennig, K.W. 2005. Convergence on a distinctive assembly mechanism by unrelated families of activating immune receptors. *Immunity* **22**: 427–438.
- Foley, B.A., De Santis, D., Van Beelen, E., Lathbury, L.J., Christiansen, F.T., and Witt, C.S. 2008. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: Implications for patient and donor suitability for haploidentical stem cell transplantations. *Blood* **112**: 435–443.
- Frazer, K.A., Ballinger, D.G., Cox, D.R., Hinds, D.A., Stuve, L.L., Gibbs, R.A., Belmont, J.W., Boudreau, A., Hardenbol, P., Leal, S.M., et al. 2007. A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**: 851–861.
- Gardiner, C.M., Guethlein, L.A., Shilling, H.G., Pando, M., Carr, W.H., Rajalingam, R., Vilches, C., and Parham, P. 2001. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. *J. Immunol.* **166**: 2992–3001.
- Gendzekhadze, K., Norman, P.J., Abi-Rached, L., Layrisse, Z., and Parham, P. 2006. High KIR diversity in Amerindians is maintained using few gene-content haplotypes. *Immunogenetics* **58**: 474–480.
- Goldstein, D.B. and Chikhi, L. 2002. Human migrations and population structure: What we know and why it matters. *Annu. Rev. Genomics Hum. Genet.* **3**: 129–152.
- Gomez-Lozano, N., Estefania, E., Williams, F., Halfpenny, I., Middleton, D., Solis, R., and Vilches, C. 2005. The silent KIR3DP1 gene (CD158c) is transcribed and might encode a secreted receptor in a minority of humans, in whom the KIR3DP1, KIR2DL4 and KIR3DL1/KIR3DS1 genes are duplicated. *Eur. J. Immunol.* **35**: 16–24.
- Guethlein, L.A., Older Aguilar, A.M., Abi-Rached, L., and Parham, P. 2007. Evolution of killer cell Ig-like receptor (KIR) genes: Definition of an orangutan KIR haplotype reveals expansion of lineage III KIR associated with the emergence of MHC-C. *J. Immunol.* **179**: 491–504.
- Gumperz, J.E., Litwin, V., Phillips, J.H., Lanier, L.L., and Parham, P. 1995. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NK1, a putative HLA receptor. *J. Exp. Med.* **181**: 1133–1144.
- Hammond, J.A., Guethlein, L.A., Abi-Rached, L., Moesta, A.K., and Parham, P. 2009. Evolution and survival of marine carnivores did not require a diversity of KIR or Ly49 NK cell receptors. *J. Immunol.* **182**: 3618–3627.
- Hansasuta, P., Dong, T., Thananchai, H., Weekes, M., Willberg, C., Aldemir, H., Rowland-Jones, S., and Braud, V.M. 2004. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. *Eur. J. Immunol.* **34**: 1673–1679.
- Hey, J. 2005. On the number of New World founders: A population genetic portrait of the peopling of the Americas. *PLoS Biol.* **3**: e193. doi: 10.1371/journal.pbio.0030193.
- Hiby, S.E., Walker, J.J., O'Shaughnessy, K.M., Redman, C.W., Carrington, M., Trowsdale, J., and Moffett, A. 2004. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. *J. Exp. Med.* **200**: 957–965.
- Hollox, E.J., Barber, J.C., Brookes, A.J., and Armour, J.A. 2008. Defensins and the dynamic genome: what we can learn from structural variation at human chromosome band 8p23.1. *Genome Res.* **18**: 1686–1697.
- Horton, R., Coggill, P., Miretti, M.M., Sambrook, J.G., Traherne, J.A., Ward, R., Sims, S., Palmer, S., Sehra, H., Harrow, J., et al. 2006. The LRC haplotype project: A resource for killer immunoglobulin-like receptor-linked association studies. *Tissue Antigens* **68**: 450–452.

- Jameson, K.A., Highnote, S.M., and Wasserman, L.M. 2001. Richer color experience in observers with multiple photopigment opsin genes. *Psychon. Bull. Rev.* **8**: 244–261.
- Kelley, J., Walter, L., and Trowsdale, J. 2005. Comparative genomics of natural killer cell receptor gene clusters. *PLoS Genet.* **1**: 129–139.
- Khakoo, S.I., Rajalingam, R., Shum, B.P., Weidenbach, K., Flodin, L., Muir, D.G., Canavez, F., Cooper, S.L., Valiante, N.M., Lanier, L.L., et al. 2000. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. *Immunity* **12**: 687–698.
- Khakoo, S.I., Geller, R., Shin, S., Jenkins, J.A., and Parham, P. 2002. The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. *J. Exp. Med.* **196**: 911–921.
- Kimura, M. and Ota, T. 1969. The average number of generations until extinction of an individual mutant gene in a finite population. *Genetics* **63**: 701–709.
- Korbel, J.O., Urban, A.E., Affourtit, J.P., Godwin, B., Grubert, F., Simons, J.F., Kim, P.M., Palejev, D., Carriero, N.J., Du, L., et al. 2007. Paired-end mapping reveals extensive structural variation in the human genome. *Science* **318**: 420–426.
- Kumar, S., Tamura, K., and Nei, M. 2004. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. *Brief. Bioinform.* **5**: 150–163.
- Kummerfeld, S.K. and Teichmann, S.A. 2005. Relative rates of gene fusion and fission in multi-domain proteins. *Trends Genet.* **21**: 25–30.
- Lanier, L.L. 2008. Evolutionary struggles between NK cells and viruses. *Nat. Rev. Immunol.* **8**: 259–268.
- Marsh, S.G., Parham, P., Dupont, B., Geraghty, D.E., Trowsdale, J., Middleton, D., Vilches, C., Carrington, M., Witt, C., Guethlein, L.A., et al. 2003. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. *Immunogenetics* **55**: 220–226.
- Martin, M.P., Bashirova, A., Traherne, J., Trowsdale, J., and Carrington, M. 2003. Cutting edge: Expansion of the KIR locus by unequal crossing over. *J. Immunol.* **171**: 2192–2195.
- Martin, D.P., Williamson, C., and Posada, D. 2005. RDP2: Recombination detection and analysis from sequence alignments. *Bioinformatics* **21**: 260–262.
- Martin, M.P., Qi, Y., Gao, X., Yamada, E., Martin, J.N., Pereyra, F., Colombo, S., Brown, E.E., Shupert, W.L., Phair, J., et al. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. *Nat. Genet.* **39**: 733–740.
- Michaelsson, J., Teixeira de Matos, C., Achour, A., Lanier, L.L., Karre, K., and Soderstrom, K. 2002. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NGG2A recognition. *J. Exp. Med.* **196**: 1403–1414.
- Middleton, D., Meenagh, A., and Gourraud, P.A. 2007. KIR haplotype content at the allele level in 77 Northern Irish families. *Immunogenetics* **59**: 145–158.
- Moesta, A.K., Norman, P.J., Yawata, M., Yawata, N., Gleimer, M., and Parham, P. 2008. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. *J. Immunol.* **180**: 3969–3979.
- Moffett, A. and Loke, C. 2006. Immunology of placentation in eutherian mammals. *Nat. Rev. Immunol.* **6**: 584–594.
- Moretta, L., Bottino, C., Pende, D., Castriconi, R., Mingari, M.C., and Moretta, A. 2006. Surface NK receptors and their ligands on tumor cells. *Semin. Immunol.* **18**: 151–158.
- Nathans, J., Piantanida, T.P., Eddy, R.L., Shows, T.B., and Hogness, D.S. 1986. Molecular genetics of inherited variation in human color vision. *Science* **232**: 203–210.
- Norman, P.J., Cook, M.A., Carey, B.S., Carrington, C.V., Verity, D.H., Hameed, K., Ramdath, D.D., Chandanayingyong, D., Leppert, M., Stephens, H.A., et al. 2004. SNP haplotypes and allele frequencies show evidence for disruptive and balancing selection in the human leukocyte receptor complex. *Immunogenetics* **56**: 225–237.
- Norman, P.J., Abi-Rached, L., Gendzekhadze, K., Korbel, D., Gleimer, M., Rowley, D., Bruno, D., Carrington, C.V., Chandanayingyong, D., Chang, Y.H., et al. 2007. Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. *Nat. Genet.* **39**: 1092–1099.
- O'Connor, G.M., Guinan, K.J., Cunningham, R.T., Middleton, D., Parham, P., and Gardiner, C.M. 2007. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. *J. Immunol.* **178**: 235–241.
- Pando, M.J., Gardiner, C.M., Gleimer, M., McQueen, K.L., and Parham, P. 2003. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. *J. Immunol.* **171**: 6640–6649.
- Parham, P. 2005. MHC class I molecules and KIRs in human history, health and survival. *Nat. Rev. Immunol.* **5**: 201–214.
- Pende, D., Biassoni, R., Cantoni, C., Verdiani, S., Falco, M., di Donato, C., Accame, L., Bottino, C., Moretta, A., and Moretta, L. 1996. The natural killer cell receptor specific for HLA-A allotypes: A novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. *J. Exp. Med.* **184**: 505–518.
- Perry, G.H., Ben-Dor, A., Tsalenko, A., Sampas, N., Rodriguez-Revenga, L., Tran, C.W., Scheffer, A., Steinfeld, I., Tsang, P., Yamada, N.A., et al. 2008. The fine-scale and complex architecture of human copy-number variation. *Am. J. Hum. Genet.* **82**: 685–695.
- Posada, D. and Crandall, K.A. 1998. MODELTEST: Testing the model of DNA substitution. *Bioinformatics* **14**: 817–818.
- Rajalingam, R., Hong, M., Adams, E.J., Shum, B.P., Guethlein, L.A., and Parham, P. 2001. Short KIR haplotypes in pygmy chimpanzee (Bonobo) resemble the conserved framework of diverse human KIR haplotypes. *J. Exp. Med.* **193**: 135–146.
- Rajalingam, R., Parham, P., and Abi-Rached, L. 2004. Domain shuffling has been the main mechanism forming new hominoid killer cell Ig-like receptors. *J. Immunol.* **172**: 356–369.
- Redon, R., Ishikawa, S., Fitch, K.R., Feuk, L., Perry, G.H., Andrews, T.D., Fiegler, H., Shapero, M.H., Carson, A.R., Chen, W., et al. 2006. Global variation in copy number in the human genome. *Nature* **444**: 444–454.
- Relethford, J.H. 2008. Genetic evidence and the modern human origins debate. *Heredity* **100**: 555–563.
- Robinson, J., Waller, M.J., Fail, S.C., and Marsh, S.G. 2006. The IMGT/HLA and IPD databases. *Hum. Mutat.* **27**: 1192–1199.
- Ronaghi, M., Karamohamed, S., Pettersson, B., Uhlen, M., and Nyren, P. 1996. Real-time DNA sequencing using detection of pyrophosphate release. *Anal. Biochem.* **242**: 84–89.
- Sambrook, J.G., Bashirova, A., Palmer, S., Sims, S., Trowsdale, J., Abi-Rached, L., Parham, P., Carrington, M., and Beck, S. 2005. Single haplotype analysis demonstrates rapid evolution of the killer immunoglobulin-like receptor (KIR) loci in primates. *Genome Res.* **15**: 25–35.
- Schneider, S., Roessli, A., and Excoffier, L. 2000. *Arlequin ver. 2.0: A software for population genetics data analysis*. Genetics and Biometry Laboratory, University of Geneva, Geneva, Switzerland.
- Shilling, H.G., Guethlein, L.A., Cheng, N.W., Gardiner, C.M., Rodriguez, R., Tyan, D., and Parham, P. 2002. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. *J. Immunol.* **168**: 2307–2315.
- Single, R.M., Martin, M.P., Gao, X., Meyer, D., Yeager, M., Kidd, J.R., Kidd, K.K., and Carrington, M. 2007. Global diversity and evidence for coevolution of KIR and HLA. *Nat. Genet.* **39**: 1114–1119.
- Snyder, M.R., Nakajima, T., Leibson, P.J., Weyand, C.M., and Goronzy, J.J. 2004. Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. *J. Immunol.* **173**: 3725–3731.
- Thananchai, H., Gillespie, G., Martin, M.P., Bashirova, A., Yawata, N., Yawata, M., Easterbrook, P., McVicar, D.W., Maenaka, K., Parham, P., et al. 2007. Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. *J. Immunol.* **178**: 33–37.
- Thomas, R., Yamada, E., Alter, G., Martin, M.P., Bashirova, A.A., Norman, P.J., Altfeld, M., Parham, P., Anderson, S.K., McVicar, D.W., et al. 2008. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? *J. Immunol.* **180**: 6743–6750.
- Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., and Higgins, D.G. 1997. The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucleic Acids Res.* **25**: 4876–4882.
- Trundle, A., Frebel, H., Jones, D., Chang, C., and Trowsdale, J. 2007. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. *Eur. J. Immunol.* **37**: 780–787.
- Uhrberg, M., Valiante, N.M., Shum, B.P., Shilling, H.G., Lienert-Weidenbach, K., Corliss, B., Tyan, D., Lanier, L.L., and Parham, P. 1997. Human diversity in killer cell inhibitory receptor genes. *Immunity* **7**: 753–763.
- Williams, F., Maxwell, L.D., Halpenny, I.A., Meenagh, A., Sleator, C., Curran, M.D., and Middleton, D. 2003. Multiple copies of KIR 3DL/S1 and KIR 2DL4 genes identified in a number of individuals. *Hum. Immunol.* **64**: 729–732.
- Wilson, M.J., Torkar, M., Haude, A., Milne, S., Jones, T., Sheer, D., Beck, S., and Trowsdale, J. 2000. Plasticity in the organization and sequences of human KIR/ILT gene families. *Proc. Natl. Acad. Sci.* **97**: 4778–4783.
- Yang, Z. 2007. PAML 4: Phylogenetic analysis by maximum likelihood. *Mol. Biol. Evol.* **24**: 1586–1591.
- Yawata, M., Yawata, N., Draghi, M., Partheniou, F., Little, A.M., and Parham, P. 2008. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK cell repertoires towards a balance of missing-self response. *Blood* **112**: 2369–2380.

Received August 29, 2008; accepted in revised form December 30, 2008.



Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes

Paul J. Norman, Laurent Abi-Rached, Ketevan Gendzekhadze, et al.

Genome Res. 2009 19: 757-769

Access the most recent version at doi:[10.1101/gr.085738.108](https://doi.org/10.1101/gr.085738.108)

Supplemental Material

<http://genome.cshlp.org/content/suppl/2009/05/01/19.5.757.DC1>

References

This article cites 78 articles, 33 of which can be accessed free at:
<http://genome.cshlp.org/content/19/5/757.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).



To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>